SCHEMBL2967967

SCHEMBL2967967

Cc1cccc(Oc2nc3cc(Br)ccc3[nH]2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 1/20 0.41
AR P10275 1/20 0.39
ALDH1A1 P00352 5/20 0.39
LMNA P02545 2/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
MAPK1 P28482 1/20 0.39
CYP1A2 P05177 2/20 0.38
CYP2C9 P11712 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
LYN P07948 1/20 0.37
PRKAG1 P54619 1/20 0.37
PRKAA2 P54646 1/20 0.37
PRKAB1 Q9Y478 1/20 0.37
MAOB P27338 1/20 0.37
ACHE P22303 1/20 0.37
MYC P01106 1/20 0.36
MAP4K4 O95819 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2959390 0.85 KDM4C (0.39) ALDH1A1MEN1KMT2AMAPK1PRKAG1
SCHEMBL16882187 0.83 AR (0.54) ARALDH1A1LMNAMEN1KMT2A
SCHEMBL2967450 0.76 LPL (0.36) ARALDH1A1LMNAMEN1KMT2A
SCHEMBL2967288 0.73 TP53 (0.53) ALDH1A1LMNAMAPTKDM4C
SCHEMBL11816656 0.72 EGFR (0.44) ALDH1A1MEN1KMT2AMAOB
SCHEMBL24074337 0.71 FABP6 (0.44) MEN1KMT2APRKAG1PRKAA2PRKAB1
SCHEMBL12241833 0.71 PRKAG1 (0.72) MEN1KMT2APRKAG1PRKAA2PRKAB1
SCHEMBL8591398 0.69 ALDH1A1 (0.67) ARALDH1A1LMNAMEN1KMT2A
SCHEMBL8982 0.69 TYMS (0.49) ALDH1A1LMNAMEN1KMT2AMAPK1
SCHEMBL569767 0.69 RAB9A (0.57) ALDH1A1LMNAMEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1973917-B1 PROTEIN KINASE INHIBITORS ABBVIE INC (US) 2015-06-10 EP disclosed
US-7772231-B2 Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors ABBOTT LABORATORIES (US) 2010-08-10 US disclosed
EP-1973917-A2 PROTEIN KINASE INHIBITORS Abbott Laboratories (US) 2008-10-01 EP disclosed
US-20070203143-A1 PROTEIN KINASE INHIBITORS ABBVIE INC. 2007-08-30 US disclosed
WO-2007079164-A2 PROTEIN KINASE INHIBITORS ABBOTT LABORATORIES (US) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070203143-A1 PROTEIN KINASE INHIBITORS PACSIN2, MAP3K20, PHKG1 PTGES 1999/4885AR 2765/4885ALDH1A1 4453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.